Dcvc Bio

Venture Capital Exempt reporting adviser

Legal name: Dcvc Bio Management Co, LLC

Palo Alto, CA Website LinkedIn X

AUM

$1.0B
Private fund assets

Private funds

4
Venture Capital 4

Private fund assets

$1.0B
Gross asset value

Employees

—

Last Form D raise

Sep 2023
Most recent fund filing

From SEC Form ADV filing (filed Mar 31, 2026). View on SEC

Investment focus

As listed in industry directories; may be out of date.

Stages
Series A
Geographies
IsraelUSACanada

People(4)

Owners and executive officers named on the firm's SEC Form ADV.

J
John Hamer
Member, Jnk Capital Management
Source: SEC Form ADV
K
Kiersten Stead
Member, Jnk Capital Management
Source: SEC Form ADV
M
Matthew Ocko
Member, Znm Capital Management
Source: SEC Form ADV
Z
Zachary Bogue
Member, Znm Capital Management
Source: SEC Form ADV

Funds(4)

Private funds reported on Form ADV, with amounts raised from the funds' SEC Form D filings.

FundTypeGross assetsRaised (Form D)InvestorsLast Form DRecency
Dcvc Bio III, L.P.Venture Capital$380.6M——Sep 2023Cold
Dcvc Bio II, L.P.Venture Capital$288.5M$350.0M33Aug 2020Cold
Dcvc Bio Opportunity Fund, L.P.Venture Capital$125.1M$350.0M33Aug 2020Cold
Dcvc Bio, L.P.Venture Capital$230.1M$208.0M41May 2019Cold

Board seats(1)

Companies whose SEC Form D filings name one of this firm's people as a director, matched by name and office ZIP code.

Atomwise
BiotechnologySan Francisco, CADirector: Kiersten Stead
$238.6M raised
Since Jul 2018
SEC Form D

Regulatory identifiers

CRD number
297640
SEC file number
802-113645

Sources